Maggie L. Shaw

Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.

Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.

A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.

Use of the RNA inhibitor givosiran was shown to reduce expression of delta-aminolevulinic acid synthase 1, in turn reducing the severity of acute attacks and chronic symptoms for patients with severe hepatic porphyria.

A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

A recent meta-analysis appearing in Journal of Cancer indicates a connection between minimal residual disease (MRD)–positive status and worse progression-free survival (PFS) and overall survival (OS) following induction and consolidation therapies.

Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).

An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries.

Our top heart failure articles of the year cover a groundbreaking development for dapagliflozin, address the important issue of disparities in this space, and see coronavirus disease 2019 make yet another appearance.

The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.

Hoping to improve outcomes among patients with acute heart failure discharged from the emergency department, study findings show that 30-day improvements from a self-care intervention were not sustainable through 90 days.

Four of our top 5 HIV articles for 2020 saw the HIV pandemic overlap with the coronavirus disease 2019 pandemic and had Anthony Fauci, MD, in common. The fifth is from this year's AIDS 2020 virtual conference, itself a product of the overlapping pandemics.

These top 5 posts from our breast cancer compendium in 2020 show that while much is known about breast cancer, much remains that can help to broaden the knowledge armamentarium.

At the recent meeting of the American Society of Hematology, results from several studies involved the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Four principal themes emerged in this study, describing why Latino/a and Black transgender women and men who have sex with men discontinued their preexposure prophylaxis (PrEP) to prevent HIV.

A 5-phase program designed to increase knowledge among patients with heart failure has shown promise in more effective disease management and hospital readmission reduction.

The panel could not reach consensus on what an expanded label might look like in an area where there are no approved therapies.

Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.

Due to a lack of comprehensive data on health literacy among these patients, a team of investigators looked at its connection with their quality of life (QOL).

Results from a 5-year study show significantly higher rates of several gastrointestinal (GI) disorders, as well as hospital-related costs, among patients living with HIV compared with controls.

Top reasons why patients with heart failure face a higher risk of hospitalization during times when fracking occurs include an increase in air pollution and stress pathways.

Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.

Research presented at this year’s annual meeting of the Radiological Society of North America shows the possible impact of food or housing insecurity on follow-up appointments for breast cancer.

Adding daratumumab to standard-of-care regimens consistently improves outcomes among patients with multiple myeloma, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

The most recent data from the CDC show a 36.6% decrease in overall mortality among individuals living with HIV; despite this progress, the virus remains a leading cause of death among certain races and ethnicities.

Overdose-related cardiac arrests rose consistently in the first few months of the coronavirus disease 2019 (COVID-19) pandemic, coming in at 48.5% above baseline through August 1, according to national emergency medical services data.

Survival after breast cancer is on the rise, thereby emphasizing the importance of discussions that focus on fertility and reproduction among younger survivors.

The 5-year risk of women dying or developing heart failure following a first severe heart attack is 20% higher compared with men, according to the findings in Circulation.